<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="maintenance dialysis or those with eGFR &amp;lt; 30 mL/min/1.73 m2." exact="Sofosbuvir" post="is the key drug of many DAA-based combinations that"/>
 <result pre="individuals also received intravenous therapy with corticosteroids (500 mg/day of" exact="methylprednisolone" post="for three consecutive days). No additional immunosuppressive medications or"/>
 <result pre="is a serious adverse event that limits its use [42]." exact="Mycophenolate mofetil" post="inhibits proliferation of T- and B-lymphocytes, thereby suppressing antibody"/>
 <result pre="thereby suppressing antibody synthesis and cell-mediated immune responses. Evidence on" exact="mycophenolate mofetil" post="for HCV-associated glomerular disease is extremely limited [43]. 10."/>
 <result pre="Intervals CKD Chronic kidney disease DAAs Direct-acting antiviral agents DCV" exact="Daclatasvir" post="3D Ritonavir-boosted paritaprevir/ombitasvir/dasabuvir EBR Elbasvir eGFR Estimated glomerular filtration"/>
 <result pre="Membranoproliferative glomerulonephritis IFN Interferon LDV Ledipasvir pegIFN Pegylated interferon RBV" exact="Ribavirin" post="RF Rheumatoid factor RT Renal transplant RTX Rituximab SIM"/>
 <result pre="Ribavirin RF Rheumatoid factor RT Renal transplant RTX Rituximab SIM" exact="Simeprevir" post="SOF Sofosbuvir SVR Sustained virological response References References 1.FabriziF.PlaisierE.SaadounD.MartinP.MessaP.CacoubP.Hepatitis"/>
 <result pre="Rheumatoid factor RT Renal transplant RTX Rituximab SIM Simeprevir SOF" exact="Sofosbuvir" post="SVR Sustained virological response References References 1.FabriziF.PlaisierE.SaadounD.MartinP.MessaP.CacoubP.Hepatitis C virus"/>
 <result pre="mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agentsHepatology20166340841710.1002/hep.2829726474537 23.SaadounD.ThibaultV.AhmedS.N.S.AlricL.MalletM.GuillaudC.IzzedineH.PlaisierA.FontaineH.CostopoulosM.et al.Sofosbuvir plus" exact="ribavirin" post="for hepatitis C-associated cryoglobulinaemia vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178"/>
 <result pre="cryoglobulinemiaAm. J. Gastroenterol.20171121298130810.1038/ajg.2017.4928291241 26.SaadounD.PolS.FerfarY.AlricL.HezodeC.AhmedS.N.S.de Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy and safety of" exact="sofosbuvir" post="plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term"/>
 <result pre="Gastroenterol.20171121298130810.1038/ajg.2017.4928291241 26.SaadounD.PolS.FerfarY.AlricL.HezodeC.AhmedS.N.S.de Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy and safety of sofosbuvir plus" exact="daclatasvir" post="for treatment of HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term outcomes of"/>
 <result pre="31.Zarębska-MichalukD.StępieńP.M.PaluchK.PabjanP.Retreatment of symptomatic HCV genotype 3 associated mixed cryoglobulinemia with" exact="sofosbuvir" post="plus ribavirin: A case reportClin. Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir"/>
 <result pre="plus ribavirin: A case reportClin. Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and" exact="daclatasvir" post="in treatment of HCV-related membranoproliferative glomerulonephritis with cryoglobulinemia in"/>
 <result pre="direct-acting antiviralsIndian J. Nephrol.20182846246430647501 34.ChiaX.X.CherepanoffS.DantaM.FurlongT.Successful treatment of HCV-related glomerulonephritis with" exact="sofosbuvir" post="and daclatasvirNephrology2018333738010.1111/nep.1308729520905 35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et al.A randomized controlled trial of"/>
 <result pre="on DAAs currently available for treatment of HCV in CKD." exact="Daclatasvir" post="(60 mg) CKD stage 1,2,3 Elbasvir/Grazoprevir (50 mg/100 mg)"/>
 <result pre="mg/120 mg) Ledipasvir/Sofosbuvir (90 mg/400 mg) Sofosbuvir/Velpatasvir (400 mg/100 mg)" exact="Simeprevir" post="(150 mg) Sofosbuvir (400 mg) Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100"/>
 <result pre="(90 mg/400 mg) Sofosbuvir/Velpatasvir (400 mg/100 mg) Simeprevir (150 mg)" exact="Sofosbuvir" post="(400 mg) Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg) Ritonavir-boosted Paritaprevir/Ombitasvir/Dasabuvir±Ribavirin(PrOD"/>
</results>
